Mauro D. I.
- Country
- Italy
- Department
- Dipartimento Oncologico Ematologico
Research Overview
- Long-term Evaluation of Givinostat in JAK2V617F Positive Chronic Myeloproliferative Neoplasms: Safety, Tolerability, and Efficacy Analysis
- A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
- Phase III Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Versus Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 35 of 161 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of multiple myeloma, including newly diagnosed cases and those with relapsed or refractory disease. Their expertise extends to innovative therapeutic approaches for patients both eligible and ineligible for autologous stem cell transplantation.
- Multiple Myeloma Management
- Transplant Medicine
- Novel Therapeutic Combinations
Their research encompasses evaluation of minimal residual disease status in multiple myeloma patients.
Myeloproliferative Disorders
The investigator focuses on treating chronic myeloproliferative neoplasms, with particular attention to cases involving the JAK2V617F mutation. Their work involves long-term therapeutic approaches for managing these chronic conditions.
- JAK2-Positive Neoplasms
- Chronic Disease Management
- Long-term Treatment Strategies
Their expertise includes monitoring long-term safety and efficacy outcomes in myeloproliferative disorders.
Advanced Therapeutics
The investigator works with cutting-edge combination therapies involving novel agents such as monoclonal antibodies and targeted treatments. Their research includes evaluation of various therapeutic combinations for optimal patient outcomes.
- Innovative Drug Combinations
- Treatment Optimization
- Response Assessment
Their work encompasses the development of new therapeutic strategies for blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.